NCT07638722
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07638722
Title Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors SWOG Cancer Research Network
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.